« Return to News | Awards & Advancement

Jazz makes management appointments

Monday, January 30, 2012 02:28 PM

Jazz Pharmaceuticals, a biopharmaceutical company specializing in products that address unmet medical needs, has appointed the following individuals to senior management positions:

Suzanne Sawochka Hooper will become general counsel and an executive officer. Hooper is currently a partner at Cooley, where she has practiced corporate and securities law since 1996. She has provided counsel to Jazz Pharmaceuticals for more than five years and was closely involved in the company's recent business combination with Azur Pharma.

Fintan Keegan has been appointed senior vice president of technical operations and will oversee the company's manufacturing, supply chain, quality and technical operations. Keegan was previously with Azur Pharma since 2006. He has over 27 years of experience in manufacturing and related technical operations.

Eunan Maguire will become senior vice president of strategy and corporate development and focus on the company's efforts to expand its product portfolio. Maguire was a co-founder of Azur Pharma and was president of U.S. operations. He has over 15 years of industry experience.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.